Active Biotech AB (ACTI) - Net Assets
Based on the latest financial reports, Active Biotech AB (ACTI) has net assets worth Skr47.20 Million SEK (≈ $5.08 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr58.20 Million ≈ $6.26 Million USD) and total liabilities (Skr11.00 Million ≈ $1.18 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Active Biotech AB (ACTI) strategic asset index to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr47.20 Million |
| % of Total Assets | 81.1% |
| Annual Growth Rate | -9.34% |
| 5-Year Change | 19.12% |
| 10-Year Change | -69.54% |
| Growth Volatility | 68.28 |
Active Biotech AB - Net Assets Trend (2000–2025)
This chart illustrates how Active Biotech AB's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see ACTI company net worth.
Annual Net Assets for Active Biotech AB (2000–2025)
The table below shows the annual net assets of Active Biotech AB from 2000 to 2025. Also explore Active Biotech AB annual equity growth to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Skr55.60 Million ≈ $5.98 Million |
+73.37% |
| 2024-12-31 | Skr32.07 Million ≈ $3.45 Million |
+4.57% |
| 2023-12-31 | Skr30.67 Million ≈ $3.30 Million |
-11.14% |
| 2022-12-31 | Skr34.51 Million ≈ $3.71 Million |
-26.06% |
| 2021-12-31 | Skr46.67 Million ≈ $5.02 Million |
+111.07% |
| 2020-12-31 | Skr22.11 Million ≈ $2.38 Million |
-58.88% |
| 2019-12-31 | Skr53.78 Million ≈ $5.79 Million |
-38.82% |
| 2018-12-31 | Skr87.92 Million ≈ $9.46 Million |
+13.18% |
| 2017-12-31 | Skr77.68 Million ≈ $8.36 Million |
-57.45% |
| 2016-12-31 | Skr182.56 Million ≈ $19.65 Million |
+1.08% |
| 2015-12-31 | Skr180.60 Million ≈ $19.44 Million |
-55.44% |
| 2014-12-31 | Skr405.31 Million ≈ $43.62 Million |
-0.03% |
| 2013-12-31 | Skr405.41 Million ≈ $43.63 Million |
+19.27% |
| 2012-12-31 | Skr339.92 Million ≈ $36.58 Million |
-32.29% |
| 2011-12-31 | Skr501.99 Million ≈ $54.02 Million |
+176.19% |
| 2010-12-31 | Skr181.76 Million ≈ $19.56 Million |
-3.65% |
| 2009-12-31 | Skr188.64 Million ≈ $20.30 Million |
+15.30% |
| 2008-12-31 | Skr163.61 Million ≈ $17.61 Million |
-13.69% |
| 2007-12-31 | Skr189.57 Million ≈ $20.40 Million |
+214.08% |
| 2006-12-31 | Skr60.36 Million ≈ $6.50 Million |
-65.86% |
| 2005-12-31 | Skr176.81 Million ≈ $19.03 Million |
+8.94% |
| 2004-12-31 | Skr162.30 Million ≈ $17.47 Million |
-43.95% |
| 2003-12-31 | Skr289.58 Million ≈ $31.16 Million |
-23.85% |
| 2002-12-31 | Skr380.27 Million ≈ $40.92 Million |
-43.98% |
| 2001-12-31 | Skr678.78 Million ≈ $73.05 Million |
+5.07% |
| 2000-12-31 | Skr646.03 Million ≈ $69.52 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Active Biotech AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5645.2% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr13.61 Million | 24.48% |
| Other Components | Skr3.56 Billion | 6406.57% |
| Total Equity | Skr55.60 Million | 100.00% |
Active Biotech AB Competitors by Market Cap
The table below lists competitors of Active Biotech AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Elementis PLC
LSE:ELM
|
$11.92 Million |
|
Japan Vietnam Medical Instrument JSC
VN:JVC
|
$11.93 Million |
|
Sun&L Co Ltd
KO:002820
|
$11.94 Million |
|
Fevertree Drinks Plc
LSE:FEVR
|
$11.94 Million |
|
KDA Group Inc
V:KDA
|
$11.90 Million |
|
Capital Partners S.A.
WAR:CPA
|
$11.89 Million |
|
Great Northern Minerals Ltd
AU:GNM
|
$11.87 Million |
|
New Era Helium Inc Common Stock
NASDAQ:NEHC
|
$11.87 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Active Biotech AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 32,070,000 to 55,600,000, a change of 23,530,000 (73.4%).
- Net loss of 37,300,000 reduced equity.
- Share repurchases of 71,800,000 reduced equity.
- New share issuances of 71,800,000 increased equity.
- Other factors increased equity by 60,830,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-37.30 Million | -67.09% |
| Share Repurchases | Skr71.80 Million | -129.14% |
| Share Issuances | Skr71.80 Million | +129.14% |
| Other Changes | Skr60.83 Million | +109.41% |
| Total Change | Skr- | 73.37% |
Book Value vs Market Value Analysis
This analysis compares Active Biotech AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 101.78x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.31x to 101.78x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2002-12-31 | Skr13.68 | Skr4.20 | x |
| 2003-12-31 | Skr5.11 | Skr4.20 | x |
| 2004-12-31 | Skr2.21 | Skr4.20 | x |
| 2005-12-31 | Skr2.08 | Skr4.20 | x |
| 2006-12-31 | Skr0.68 | Skr4.20 | x |
| 2007-12-31 | Skr1.99 | Skr4.20 | x |
| 2008-12-31 | Skr1.85 | Skr4.20 | x |
| 2009-12-31 | Skr1.81 | Skr4.20 | x |
| 2010-12-31 | Skr1.56 | Skr4.20 | x |
| 2011-12-31 | Skr4.11 | Skr4.20 | x |
| 2012-12-31 | Skr2.77 | Skr4.20 | x |
| 2013-12-31 | Skr3.02 | Skr4.20 | x |
| 2014-12-31 | Skr2.97 | Skr4.20 | x |
| 2015-12-31 | Skr1.20 | Skr4.20 | x |
| 2016-12-31 | Skr1.21 | Skr4.20 | x |
| 2017-12-31 | Skr0.51 | Skr4.20 | x |
| 2018-12-31 | Skr0.52 | Skr4.20 | x |
| 2019-12-31 | Skr0.27 | Skr4.20 | x |
| 2020-12-31 | Skr0.13 | Skr4.20 | x |
| 2021-12-31 | Skr0.19 | Skr4.20 | x |
| 2022-12-31 | Skr0.13 | Skr4.20 | x |
| 2023-12-31 | Skr0.11 | Skr4.20 | x |
| 2024-12-31 | Skr0.08 | Skr4.20 | x |
| 2025-12-31 | Skr0.04 | Skr4.20 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Active Biotech AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -67.09%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.26x
- Recent ROE (-67.09%) is above the historical average (-95.42%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2001 | 4.86% | 32.29% | 0.14x | 1.10x | Skr-34.86 Million |
| 2002 | -78.60% | 0.00% | -0.01x | 1.23x | Skr-336.92 Million |
| 2003 | -106.22% | -91820.60% | 0.00x | 1.19x | Skr-336.56 Million |
| 2004 | -107.35% | -249.88% | 0.22x | 1.93x | Skr-190.46 Million |
| 2005 | -76.59% | -1479.62% | 0.02x | 3.21x | Skr-153.10 Million |
| 2006 | -230.59% | -209.74% | 0.14x | 7.66x | Skr-145.22 Million |
| 2007 | -109.57% | -1719.95% | 0.02x | 2.58x | Skr-226.68 Million |
| 2008 | -110.99% | -339.69% | 0.11x | 2.89x | Skr-197.95 Million |
| 2009 | -118.73% | -2079.25% | 0.02x | 2.64x | Skr-242.84 Million |
| 2010 | -121.63% | -1946.68% | 0.02x | 2.77x | Skr-239.24 Million |
| 2011 | -18.84% | -40.30% | 0.27x | 1.71x | Skr-144.75 Million |
| 2012 | -51.49% | -79.88% | 0.31x | 2.05x | Skr-209.01 Million |
| 2013 | -52.31% | -196.11% | 0.14x | 1.89x | Skr-252.63 Million |
| 2014 | -57.12% | -10221.28% | 0.00x | 1.78x | Skr-272.04 Million |
| 2015 | -107.16% | -1189.13% | 0.04x | 2.49x | Skr-211.59 Million |
| 2016 | -32.64% | -312.91% | 0.05x | 2.26x | Skr-77.84 Million |
| 2017 | -140.06% | -537.36% | 0.07x | 3.91x | Skr-116.56 Million |
| 2018 | -41.95% | -183.92% | 0.07x | 3.44x | Skr-45.67 Million |
| 2019 | -67.06% | -428.08% | 0.13x | 1.24x | Skr-41.44 Million |
| 2020 | -145.24% | -477.58% | 0.21x | 1.45x | Skr-34.33 Million |
| 2021 | -106.88% | -801.33% | 0.11x | 1.22x | Skr-54.55 Million |
| 2022 | -170.06% | 0.00% | 0.00x | 1.48x | Skr-62.14 Million |
| 2023 | -149.35% | 0.00% | 0.00x | 1.44x | Skr-48.87 Million |
| 2024 | -122.86% | 0.00% | 0.00x | 1.35x | Skr-42.61 Million |
| 2025 | -67.09% | 0.00% | 0.00x | 1.26x | Skr-42.86 Million |
Industry Comparison
This section compares Active Biotech AB's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $51,243,889
- Average return on equity (ROE) among peers: -133.60%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Active Biotech AB (ACTI) | Skr47.20 Million | 4.86% | 0.23x | $11.91 Million |
| 2cureX AB (2CUREX) | $13.62 Million | -53.33% | 0.76x | $1.13 Million |
| Ascelia Pharma AB (publ) (ACE) | $111.73 Million | -21.83% | 0.04x | $7.82 Million |
| AcouSort AB (ACOU) | $8.46 Million | -178.16% | 0.46x | $6.29 Million |
| Alzinova AB (ALZ) | $121.96 Million | -21.54% | 0.18x | $9.10 Million |
| AlzeCure Pharma (ALZCUR) | $32.97 Million | -235.89% | 0.38x | $95.97 Million |
| Annexin Pharmaceuticals AB (ANNX) | $13.71 Million | -366.46% | 0.39x | $9.68 Million |
| Alligator Bioscience AB (ATORX) | $68.52 Million | -112.06% | 0.43x | $2.35 Million |
| BioInvent International AB (BINV) | $29.45 Million | -307.87% | 0.85x | $158.63 Million |
| BioArctic AB (publ) (BIOA-B) | $60.76 Million | 94.77% | 10.65x | $2.60 Billion |
About Active Biotech AB
Active Biotech AB (publ), a biotechnology company, engages in the research, development, production, marketing, and sale of medical, chemical, and biotechnology products in Sweden. It is developing Tasquinimod, a small molecule immunomodulator, which is in Phase II clinical trial to treat hematological malignancies; Laquinimod, an immunomodulator for the treatment of severe inflammatory eye disea… Read more